01-19509. Mylan Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 66 Abbreviated New Drug Applications
-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA) is withdrawing approval of 66 abbreviated new drug applications (ANDAs). The holders of the applications notified the agency in Start Printed Page 41030writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
DATES:
Effective September 5, 2001.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Florine P. Purdie, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.
ANDA No. Drug Applicant 61-755 Ampicillin Capsules USP, 250 milligrams (mg) and 500 mg. Mylan Pharmaceuticals, Inc., 781 Chestnut Ridge Rd., P.O. Box 4310, Morgantown, WV 26504. 62-090 Amoxicillin for Oral Suspension USP, 125 mg/5 milliliters (mL) and 250 mg/5 mL. Do. 62-928 Clindamycin Phosphate Injection USP, 150 mg/mL. AstraZeneca, 725 Chesterbrook Blvd., Wayne, PA 19087-5677. 63-167 Amikacin Sulfate Injection USP, 50 mg (base)/mL. Do. 63-169 Amikacin Sulfate Injection USP, 250 mg (base)/mL. Do. 70-095 Furosemide Injection USP, 10 mg/mL. Do. 70-096 Furosemide Injection USP, 10 mg/mL. Do. 70-529 Indomethacin Capsules USP, 25 mg. Watson Laboratories, Inc., 311 Bonnie Circle, Corona, CA 92880. 70-530 Indomethacin Capsules USP, 50 mg. Do. 70-645 Metoclopramide Tablets, 10 mg. Do. 71-920 Methyldopa and Hydrochlorothiazide Tablets USP, 250 mg/15 mg. Do. 71-921 Methyldopa and Hydrochlorothiazide Tablets USP, 250 mg/25 mg. Do. 71-922 Methyldopa and Hydrochlorothiazide Tablets USP,500 mg/30 mg. Do. 71-923 Methyldopa and Hydrochlorothiazide Tablets USP, 500 mg/50 mg. Do. 72-023 Metaproterenol Sulfate Syrup USP, 10 mg/5 mL. Muro Pharmaceuticals, Inc., 890 East St., Tewksbury, MA 01876. 72-081 Naloxone Hydrochloride (HCl) Injection USP, 0.02 mg/mL. AstraZeneca. 72-086 Naloxone HCl Injection USP, 0.4 mg/mL. Do. 72-091 Naloxone HCl Injection USP, 1 mg/mL. Do. 72-165 Fenoprofen Tablets USP, 600 mg. Watson Laboratories, Inc. 72-293 Fenoprofen Capsules USP, 300 mg. Do. 72-294 Fenoprofen Capsules USP, 200 mg. Do. 72-372 Duphalac (Lactulose Solution USP), 10 grams/15 mL. Solvay Pharmaceuticals, Inc., 901 Sawyer Rd., Marietta, GA 30062. 73-062 Loperamide HCl Oral Solution, 1 mg/5 mL. Watson Laboratories, Inc. 73-106 Acetaminophen Suppositories USP, 120 mg. Able Laboratories, Inc.,6 Hollywood Ct., South Plainfield, NJ 07080. 73-107 Acetaminophen Suppositories USP, 325 mg. Do. 73-108 Acetaminophen Suppositories USP, 650 mg. Do. 73-120 Albuterol Tablets USP, 2 mg. Medeva Pharmaceuticals, Inc., 3501 West Garry Ave., Santa Ana, CA 92704. 73-121 Albuterol Tablets USP, 4 mg. Do. 73-165 Albuterol Sulfate Syrup, 2 mg/5 mL. Watson Laboratories, Inc. 73-381 Carbidopa and Levodopa Tablets USP, 10 mg/100 mg. Do. 73-382 Carbidopa and Levodopa Tablets USP, 25 mg/100 mg. Do. 73-383 Carbidopa and Levodopa Tablets USP, 25 mg/250 mg. Do. 73-651 Piroxicam Capsules USP,10 mg and 20 mg. Roxane Laboratories, Inc., P.O. Box 16532, Columbus, OH 43216. 74-156 Gemfibrozil Tablets USP, 600 mg. Watson Laboratories, Inc. 74-199 Alprazolam Tablets USP, 0.25 mg, 0.5 mg, and 1 mg. Roxane Laboratories, Inc. 74-319 Naproxen Sodium Tablets USP. Purepac Pharmaceutical Co., 200 Elmora Ave., Elizabeth, NJ 07207. 74-570 Acyclovir Capsules USP, 200 mg. Roxane Laboratories, Inc. 74-897 Acyclovir Sodium for Injection, USP. Apothecon, Inc., P.O. Box 4500,Princeton, NJ 08543. 74-972 Cimetidine Tablets USP, 100 mg. L. Perrigo Co.,515 Eastern Ave., Allegan, MI 49010. 80-109 Sulfisoxazole Tablets USP, 500 mg. Impax Laboratories, Inc., 30831 Huntwood Ave., Hayward, CA 94544. 80-782 Prednisone Tablets USP, 5 mg. Do. 83-080 Aquasol A (Vitamin A Capsules USP). AstraZeneca. 83-857 Estratab Esterified Estrogens Tablets USP, 2.5 mg. Solvay Pharmaceuticals, Inc. 84-574 Aminophylline Tablets, 100 mg. Impax Laboratories, Inc. 84-576 Aminophylline Tablets, 200 mg. Do. 84-922 Hydralazine HCl Tablets USP, 25 mg. Do. 85-171 Glutethimide Tablets USP, 500 mg. Medeva Pharmaceuticals, Inc. 85-264 Bronkodyl (Theophylline Capsules USP), 100 mg and 200 mg. Sanofi-Synthelabo, Inc., 90 Park Ave., 6th Fl., New York, NY 10016. 85-376 Dexamethasone Tablets USP, 0.75 mg. Impax Laboratories, Inc. Start Printed Page 41031 85-544 Diethylpropion HCl Tablets USP, 25 mg. Medeva Pharmaceuticals, Inc. 85-864 Amitriptyline HCl Tablets USP, 10 mg. Do. 85-935 Amitriptyline HCl Tablets USP, 25 mg. Do. 85-936 Amitriptyline HCl Tablets USP, 50 mg. Do. 86-335 Amitriptyline HCl Tablets USP, 150 mg. Do. 86-336 Amitriptyline HCl Tablets USP, 100 mg. Do. 86-337 Amitriptyline HCl Tablets USP, 75 mg. Do. 87-156 Fluonid (Fluocinolone Acetonide) Cream, 0.025%. Allergan, 2525 Dupont Dr., P.O. Box 19534, Irvine, CA 92623. 87-157 Fluonid (Fluocinolone Acetonide) Ointment, 0.025%. Do. 88-075 Amitriptyline HCl Tablets, 10 mg. Purepac Pharmaceutical Co. 88-076 Amitriptyline HCl Tablets, 25 mg. Do. 88-077 Amitriptyline HCl Tablets, 50 mg. Do. 88-078 Amitriptyline HCl Tablets, 75 mg. Do. 88-079 Amitriptyline HCl Tablets, 100 mg. Do. 88-215 Penecort (Hydrocortisone) Gel, 1%. Allergan 88-217 Penecort (Hydrocortisone) Ointment, 2.5%. Do. 89-495 Hydrocortisone Lotion USP, 1%. Beta Dermaceuticals, Inc., P.O. Box 691106, San Antonio, TX 78269. Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective September 5, 2001.
Start SignatureDated: July 24, 2001.
Janet Woodcock,
Director, Center for Drug Evaluation and Research.
[FR Doc. 01-19509 Filed 8-3-01; 8:45 am]
BILLING CODE 4160-01-S
Document Information
- Effective Date:
- 9/5/2001
- Published:
- 08/06/2001
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 01-19509
- Dates:
- Effective September 5, 2001.
- Pages:
- 41029-41031 (3 pages)
- Docket Numbers:
- Docket No. 01N-0317
- PDF File:
- 01-19509.pdf